Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology (NASDAQ: CSBR), a global provider of preclinical and clinical research services, will announce its financial and operational results for Q4 and the fiscal year ended April 30, 2024, on July 18, 2024, after market close.
The company will hold a conference call at 4:30 P.M. EST (1:30 P.M. PST) to discuss the results. Participants can join the call domestically by dialing 888-506-0062 or internationally at 973-528-0011 using access code 135832. A replay will be available within 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode: 50895, or through the investor section of the company's website.
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims to advance radionuclide therapies, offering new hope for cancer patients. This synergy addresses the need for combined specialized expertise and clinically relevant models in radioligand therapies, positioning both organizations to drive significant advancements in the field.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.